Hit enter to search or ESC to close
MaaT Pharma
  • About us
  • Technology
  • Pipeline
  • News
  • Contact
  • Investors
MaaT Pharma
Press Releases

MaaT Pharma Annonce 18 millions d’euros de Financement Série B pour l’Expansion de son Développement Clinique de Médicaments Biologiques « Microbiote »

Lyon, le 5 février 2020 - MaaT Pharma annonce aujourd'hui une levée de fonds de…
nboutaoui
nboutaouiFebruary 4, 2020
Press Releases

MaaT Pharma Announces €18 Million Series B Financing Round to Support Further Clinical Development of Microbiome Biotherapeutics

Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B…
nboutaoui
nboutaouiJanuary 31, 2020
Posters

Posters – ASH 2019

nboutaoui
nboutaouiDecember 7, 2019
Press Releases

MaaT Pharma announces the presentation of data with its Lead Microbiota Biotherapeutic in intestinal GvHD at 61st American Society of Hematology (ASH) Annual Meeting

  Lyon, France, November 6, 2019 – MaaT Pharma announced today that a poster will…
nboutaoui
nboutaouiNovember 6, 2019
Press Releases

MaaT Pharma Expands Executive Team to Strengthen Corporate Development and Accelerate Expansion of Microbiome Data Science Platform GutPrint

Jean-Marc Renard, MS, MBA, joins as Chief Business Officer  Emmanuel Prestat, PhD, joins as Computational…
nboutaoui
nboutaouiSeptember 10, 2019
Posters

An evaluation of binning methods to recover human gut microbial pan-genomes from non-redundant reference gene catalog

nboutaoui
nboutaouiJuly 24, 2019
Press Releases

MaaT Pharma Completes Third Positive DSMB Assessment Setting High Safety Standard for Human Intestinal Microbiome Whole Ecosystem-Based Therapeutics

Independent Data Safety Monitoring Board (DSMB) confirms continuation of Phase II HERACLES study in acute…
nboutaoui
nboutaouiJune 24, 2019
Business Update

Statement following recently FDA reported event with FMT in USA

We recognize that the FDA has sent out an alert regarding the death of a…
nboutaoui
nboutaouiJune 14, 2019
Business Update

Communication suite à l’alerte de sécurité rapportée par la FDA sur un décès lié à une FMT aux Etats-Unis

Nous avons pris note de l’alerte lancée par la FDA (USA) concernant le décès d'un…
nboutaoui
nboutaouiJune 14, 2019
Press Releases

MaaT Pharma Expands Patent Portfolio with Three Granted Patents Covering its Microbiome Restoration Biotherapeutic Platform

- First patents to cover the fundamental processes for accessing the human gut microbiome as…
nboutaoui
nboutaouiMay 21, 2019
NextPrevious »

Categories

  • Business Update (2)
  • Media (12)
  • Posters (8)
  • Press Releases (33)

MAAT PHARMA

  • Legal
  • Careers

COMPANY

  • Home
  • About Us
  • Technology
  • Pipeline
  • Partnership

RESSOURCES

  • News
  • Playing Cards

CONTACT

  • Contact Us
  • Twitter
  • Facebook
  • Linkedin

© 2020 MaaT Pharma. MaaT Pharma’s mission is to restore microbiome function to treat life-threatening diseases

  • About us
  • Technology
  • Pipeline
  • News
  • Contact
  • Investors